Understanding the temporal and pharmacodynamic effects of PIK3 inhibition in ER+ breast cancer is fundamental to develop a rationale for treatment scheduling to improve at maximum therapeutic index. The gene discussed is PIK3CG; the disease is breast carcinoma.